Tirzepatide Side Effects: What Studies Found
Which Tirzepatide side effects showed up most?
Studies most often found less hunger, diarrhea, nausea, vomiting, and constipation. Tirzepatide side effects were worse while doses rose. Most weren’t severe.
Reviewers combined nine trials with 9,871 people. They found nearly twice the gallbladder or bile-duct risk seen in other groups [6]. The problem was still uncommon for most people.
The label’s strongest warning concerns one thyroid cancer. Rats developed thyroid cell tumors, but human studies haven’t found that harm. The label doesn’t allow the drug if you or a close family member has had that cancer. Multiple endocrine neoplasia type 2 also keeps someone from using the drug. This inherited illness can make tumors grow in several glands [7].
First come the common problems. Then come the serious warnings, the loss of muscle, and pounds returning.
You’ll need your health record to help your doctor judge which risks matter most.
What did Tirzepatide trials count as side effects?
The phase 3 trials were large late studies after early safety work. They counted hard stools, nausea, low hunger, vomiting, and diarrhea. These were the best-recorded Tirzepatide side effects. They also led many people to leave a study.
A 2023 review gathered stomach and bowel findings available through 2023 [8]. It didn’t find a new kind of trouble.
A 2026 check used FDA reports filed from 2022 through 2025. Stomach and bowel trouble ranked first. Skin trouble at the shot spot ranked second. People and health workers sent more than 19,000 shot-site reports [9]. That’s a count of reports, not people. Reports can raise a flag but can’t give the true rate.
In 2025, a review covered trials available through 2025. It found more stomach and bowel trouble with tirzepatide than placebo. The adults had obesity without diabetes [1]. Another report appeared in 2026 after tracking cases up to its 2026 cutoff. Half its cases began by about day 16. Most arrived during the opening three months [9]. That’s when the amount still rises.
Give the care team each symptom. One report can’t show its cause.
Which serious Tirzepatide problems need context?
The label and safety reviews focus most on these problems.
Gallbladder and bile-duct trouble. A 2023 review joined trials with 9,871 people. It found nearly twice the risk seen in other groups. Reviewers were 95% sure the added illness wasn’t chance [6]. A 2025 review also found more bile trouble and gallstones [19]. Fast weight loss can form gallstones too.
Thyroid cell tumors. Findings in rats led to the label’s strongest warning. Related drugs caused more tumors with larger amounts and longer use. People haven’t shown that harm. This cancer in you or your family rules the drug out. Multiple endocrine neoplasia type 2, often called MEN-2, also rules it out [7]. That family illness can grow tumors in more than one gland. A 2026 review used evidence available in 2026. It called the risk in people unproven [18].
Other cancers. A 2025 review used trials available through 2025 [20]. It looked for cancer in people with and without diabetes. The thyroid warning still rests on animals, not proven human harm.
Muscle and other tissue loss. A SURMOUNT-1 scan found about 25% of weight lost in 2025 wasn’t fat [10]. In a wider 2026 review, half the studies put muscle below 28% of lost weight, and half put it above [15]. A 2024 review compared the loss with more than ten years of normal aging. Strength work mattered too [16]. No review can name your exact loss.
Weight return after stopping. Some SURMOUNT-4 volunteers moved to placebo in 2024 and regained weight [14]. Those who stayed on tirzepatide kept losing. A later SURMOUNT-4 check in 2026 found heart and blood-sugar risks worsened as weight returned [22].
Leaving treatment after unwanted effects. A 2026 review of three direct studies found about 32% more people quit tirzepatide than the other drug [37]. A 2025 FDA report study found wrong-dose use was reported most often [21]. Reports show where mistakes occur, not what caused each one.
Your past illnesses matter because studies can’t know your full history.
When can Tirzepatide cause diarrhea?
Diarrhea is one of four main stomach and bowel effects. The others are nausea, vomiting, and hard stools. In user reports, about 17–25% mention loose stools. Users often put the peak around the fourth day. A trial didn’t test that account.
A 2024 SURPASS check found stomach trouble didn’t explain the weight loss. People with these problems and those without them lost much the same amount [35]. You don’t have to feel sick for the drug to affect weight.
A study finished in 2025 and its paper appeared in 2025. It followed when symptoms came and went. Trouble was worst while amounts rose. It often eased once the amount held steady [38].
The label begins at 2.5 mg for four weeks. It then allows another 2.5 mg step after four more weeks. That slow pace aims to make stomach trouble easier to bear. Faster increases weren’t part of the main trials.
Track symptoms without using sickness as a sign of weight loss. Symptoms can’t prove effect.
What must your care team know about Tirzepatide?
Two less common situations matter when you plan care.
Before an operation. Tirzepatide belongs with GLP-1 drugs, which copy one gut hormone. It may make your stomach empty more slowly. On day five, roughly half remains in your blood. Anesthesia is medicine that keeps you fully asleep during surgery. Food left there could reach your lungs. A 2024 review discussed waiting longer without food, scanning your stomach, or using medicine to move a meal onward. The paper covered work available in 2024 [13]. Actual lung cases are rare. Give every medicine name to the surgery team.
Birth-control pills. These pills may work less well when treatment begins or the amount goes up. The FDA label gives other birth-control steps during those times [7]. Your prescriber can explain how the steps fit your case.
Water loss and your kidneys. Long or severe vomiting and diarrhea can dry you out. That can hurt your kidneys. The risk is greater if you’re already dry or take some blood-pressure drugs. Large studies haven’t shown a clear rise in kidney injury. A 2026 review found fewer kidney problems in some high-risk groups [18]. It didn’t prove the drug will help your kidneys. Severe fluid loss remains the concern.
Your care team will need your full drug list.